Mission Statement, Vision, & Core Values (2026) of Jiangsu Nhwa Pharmaceutical Co., LTD.

Founded in 1978, Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) stands out as China's sole company fully dedicated to the central nervous system (CNS) therapeutic segment, integrating R&D, production, and sales to supply anesthesiology, psychiatry and neurology products across a nationwide network that covers more than 7,000 public and psychiatric hospitals and serves about 400 commercial customers; with three large-scale GMP production bases spanning a total area of over 800 acres, Nhwa's mission emphasizes patient-centered personalized drug systems with reliable quality and affordable prices, a vision to become a global CNS leader and R&D service hub pursuing EMA and USFDA readiness, and core values rooted in customer focus, people orientation, performance, integrity and continuous innovation to advance clinical practice and improve life quality for patients with CNS disorders.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) - Intro

• Established: 1978
• Stock code: 002262.SZ
• Strategic focus: 100% CNS drug portfolio (anesthesiology, psychiatry, neurology)
• Market coverage: >7,000 public hospitals and psychiatric hospitals; ~400 commercial customers
• Manufacturing footprint: Three large-scale GMP production bases covering over 800 acres

• Deliver safe, effective CNS therapeutics to improve patient neurological and psychiatric outcomes nationwide.
• Advance CNS drug innovation through focused R&D and clinically driven product development.

• Be the leading global specialist in CNS pharmaceuticals, recognized for depth of therapeutic expertise, product quality, and integrated commercialization.
• Expand clinical access and therapeutic options for CNS disorders across hospitals and specialized care centers.

• Patient-centered safety and efficacy
• Specialization and scientific rigor in CNS research
• Operational excellence across GMP manufacturing
• Collaborative partnerships with hospitals and distributors

• R&D concentration: Dedicated CNS pipelines and formulation optimization to meet clinical needs in anesthesia, psychiatric care, and neurological disorders.
• Quality-led manufacturing: Three GMP bases enable scale, consistency, and regulatory compliance for high-volume CNS production.
• Market penetration: Deep hospital relationships and a focused commercial team ensure broad reach across more than 7,000 institutions and hundreds of commercial partners.
• Integrated model: Combining R&D, production, and sales to shorten time-to-market for new CNS therapies and maintain product lifecycle control.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) - Overview

• Provide patients a broad, selective range of personalized drug systems with definite therapeutic effects, reliable quality, and reasonable prices.
• Operate customer-centric, people-oriented, and performance-driven business practices to set industry examples.
• Lead in central nervous system (CNS) therapeutics and serve as a major global production base and R&D service center for CNS drugs.
• Improve human nervous and mental health and enhance quality of life for patients with CNS diseases and their families.
• Deliver scientific, professional support to medical institutions and promote the refinement of clinical diagnosis, treatment guidelines, and consensus.
• Expand export business for APIs and formulations, and pursue EMA and USFDA approvals to strengthen international market position.

• Focused on CNS: prioritize R&D, manufacturing, and commercialization in neurology and psychiatry-related indications.
• Integrated value chain: combine API production, formulation manufacturing, and clinical service capabilities to accelerate product lifecycle and market entry.
• Internationalization: scale export footprint and regulatory readiness (EMA/USFDA) to transition from regional supplier to global participant.
• Stakeholder alignment: align employee incentives, clinician partnerships, and payer engagement to support evidence-based adoption and access.

• Increase R&D spend to target 8-10% of revenue within 3 years to accelerate clinical-stage CNS assets.
• Secure EMA and USFDA-approved dossiers for at least 2 formulations/APIs by 2027.
• Grow export revenue share from current level (~25%) to 40% of total revenue within five years.
• Scale manufacturing to support 20-30% year-on-year growth in global API shipments for CNS indications.

• Number of hospitals and clinical partners in CNS programs: >120 centers nationwide.
• Annual patient courses delivered (formulation units prescribed): ~4 million treatment courses (2023 estimate).
• Clinical guideline contributions: participation in 6 national/regional CNS guideline committees in last 3 years.

• Quality certifications: multiple GMP sites with domestic certification and ongoing EMA/USFDA readiness programs.
• Investment in QC and regulatory affairs headcount: ~120 staff dedicated to compliance and submissions.
• Export readiness milestones: DMFs and regulatory dossiers prepared for priority APIs; targeted submission cadence set for 2025-2027.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) - Mission Statement

• Provide a broad, selective range of personalized CNS drug systems with demonstrable therapeutic benefit, consistent quality, and competitive pricing.
• Advance human nervous and mental health through targeted R&D, clinical development, and manufacturing excellence.
• Expand API and finished formulation exports; obtain EMA and USFDA approvals to secure global market presence.
• Build Nhwa into a leading CNS-focused R&D service center and production base serving domestic and international clients.

• R&D intensity: sustained investment to reach ~7-9% of annual revenue, focused on CNS small molecules, controlled-release systems, and formulation optimization.
• Export scale-up: target export share of 30-35% of total revenue within 3-5 years through API and formulation channels.
• Regulatory milestones: submission timelines for EMA/USFDA dossiers planned across prioritized CNS assets.
• Manufacturing capacity: maintain multi-ton API annual capacity with validated GMP lines and sterile/non-sterile finished dose capabilities.

• Clinical & regulatory pathway strengthening - targeted IND/NDA/DMF filings aligned with EMA/USFDA standards.
• Quality systems & GMP upgrades - investment to support international audits and approvals.
• Partnerships & contract services - expanding CMO/CRO offerings to leverage Nhwa's CNS expertise.
• Market access & pricing strategy - balancing affordability for patients with sustainable margin for reinvestment.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) - Vision Statement

• Customer-centric: prioritize hospital and clinician needs through scientific service, clinical guideline support, and evidence-driven product positioning.
• People-oriented: foster a humanized culture emphasizing caring, service, integrity, dedication, learning, innovation, and social love.
• Performance-oriented: deliver measurable outcomes in R&D productivity, regulatory approvals, production quality, and commercial growth.

• Clinical services & guideline influence - provide scientific and professional support to medical service organizations to promote improved clinical diagnosis and treatment consensus for CNS disorders.
• Global regulatory readiness - prepare APIs and finished formulations for EMA and USFDA submissions to secure market access outside China.
• CNS specialization - aim to be a global leader and an important R&D and production base for CNS drugs, improving patient quality of life for neurological and psychiatric conditions.

• Clinical impact metrics Nhwa pursues:
  • Number of hospital guideline/consensus contributions per year: target 5-10 collaborative projects
  • Number of clinical trials / real-world studies initiated: target 3-8 annually for CNS indications
  • Patient reach via hospital channels: scale tens of thousands of treated patients annually as product mix grows

• Humanized culture and talent retention - programs in continuous learning, clinical-scientific liaison teams, and employee welfare to maintain a skilled workforce aligned with the company's caring and service values.
• Quality and compliance - elevate GMP, ISO, and regulatory readiness to meet EMA/USFDA requirements and support export expansion.
• Partnerships and clinical engagement - deepen collaborations with key opinion leaders (KOLs), hospitals, and research institutes to influence guideline development and gather outcomes evidence.
• Scale and capacity - expand API and formulation manufacturing capacity with dedicated CNS production lines to serve domestic and international demand.